Arena Pharmaceuticals, Inc. (ARNA) Reports In-Line Q2 Loss of 16c/Share
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Price: $99.98 --0%
Financial Fact:
Net loss per share allocable to common stockholders, diluted: -0.05
Today's EPS Names:
JAGX, CLIR, ZTO, More
Financial Fact:
Net loss per share allocable to common stockholders, diluted: -0.05
Today's EPS Names:
JAGX, CLIR, ZTO, More
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported Q2 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $3.26 million versus the consensus estimate of $3.35 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
- Coty (COTY) Misses Q4 EPS by 1c, offers outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
